ITF2357 has recently been reported to exert a targeting effect on oncogenic BRAF in melanoma cells (Celesia et al., 2022) and affect oncogenic BRAF and p53 interplay, thus representing a promising candidate for melanoma-targeted therapy (Celesia et al., 2023). Here, TP53 is linked to melanoma.